Çѱ¹ÀÀ¿ë¾à¹°ÇÐȸ ½Å¾à°³¹ßÀü¹®°¡ ¾ç¼º ±³À° ÇÁ·Î±×·¥: ±âº»°úÁ¤
»çȸ: ±è¼ÒÈñ ±³¼ö (¾ÆÁÖ´ëÇб³ ¾àÇдëÇÐ)
Time | Program |
---|---|
09:30- | ±³À°ÇÁ·Î±×·¥ Á¢¼Ó |
10:00-10:10 | Opening Remark Greeting from President of KSAP |
Session 1: ¾àÈ¿ ¹× ¾ÈÀü¼º Æò°¡ÀÇ ÀÌÇØ | |
10:10-10:55 | ½Å¾à °³¹ß¿¡¼ Ç×¾ÏÁ¦ÀÇ À¯È¿¼º Æò°¡
¢º ±è¿ì¼÷ ¹Ú»ç / LGÈÇÐ »ý¸í°úÇлç¾÷º»ºÎ ½Å¾à¿¬±¸¼Ò
Evaluating Efficacy of Anti-cancer Agents in Drug Development |
10:55-11:10 | Q & A |
11:10-11:55 | Èĺ¸¹°Áú ÃÖÀûÈ ´Ü°è¿¡¼ÀÇ ºñÀÓ»ó °í·Á»çÇ× ¢º ±è¼öÇå ´ëÇ¥ / (ÁÖ)Å¥º£½ºÆ®¹ÙÀÌ¿À
Considerations and Strategies for Lead Optimization |
11:55-12:10 | Q & A |
12:10-13:30 | Lunch |
Session 2: ¾àµ¿ÇÐÀÇ ÀÌÇØ ¹× ÆÄ¶ó¹ÌÅÍ °³³ä | |
13:30-14:15 |
¾àµ¿ÇÐ ÀÌÇØ ¹× ADME Overview
¢º ±è¼ÒÈñ ±³¼ö / ¾ÆÁÖ´ëÇб³ ¾àÇдëÇÐUnderstanding Pharmacokinetics & Overview of ADME |
14:15-14:30 | Q & A |
14:30-15:15 |
ÁÖ¿ä ¾àµ¿ÇÐ ÁÖ¿ä ÆÄ¶ó¸ÞÅÍÀÇ °³³ä
¢º ±è¼ÒÈñ ±³¼ö / ¾ÆÁÖ´ëÇб³ ¾àÇдëÇÐConcept of Main Pharmacokinetic Parameters |
15:15-15:30 | Q & A |
15:30-15:40 | Intermediate Break |
Session 3: ½Å¾à°³¹ß ½Ç¹«Àü·« | |
15:40-16:25 | ¾à¹° ÀçâÃâ¿¡ ÀÖ¾î¼ÀÇ Æ¯Çã ¢º ÀåÁ¤¼ö º¯¸®»ç / ƯÇã¹ýÀÎ ÇʾؿÂÁö
Patents in Drug Repositioning |
16:25-16:40 | Q & A |
16:40-17:25 | ½Å¾à Çã°¡½É»ç ¢º ±èÈ£Á¤ °úÀå / ½ÄǰÀǾàǰ¾ÈÀüÆò°¡¿ø ¼øÈ¯½Å°æ°è¾àǰ°ú
MFDS¡¯s New Drug Application Review |
17:25-17:40 | Q & A |
17:40- | Closing Remark |